Information on selecting the most advantageous offer - request for proposal number RFP 022897 – SYNTHESIS AND OPTIMIZATION OF POLYOLIGONUCLEOTIDES IN TERMS OF EFFICIENT PRODUCTION IN DIFFERENT EXPRESSION SYSTEMS

In connection with the co-financing of the project entitled „Development of novel mRNA/VLP-based vaccines against emerging zoonotic viral diseases” financed by the State budget from the Medical Research Agency (no. 2021 / ABM / 05 / 00001-00) as part of the Competition: Development of innovative therapeutic solutions using RNA technology, pursuant to § 8 sec. 2 point 2) of the co-financing agreement, Adamed Pharma S.A.. informs that the contract will be awarded to the following company that have presented the most advantageous offer:

• Eurofins Genomics AT GmbH